Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2011

View Archived Issues

Johnson & Johnson recaps highlights of third quarter 2011

German research team presents new cyclin-dependent kinase 9 inhibitors

Ligand Pharmaceuticals and Sage Therapeutics enter licensing agreement

Analysis of TIRASMUS data identifies possible marker of temsirolimus efficacy in colorectal cancer

FDA accepts Lymphoseek NDA for review

Further phase I data reported on GDC-941 in metastatic and advanced cancer

New antibacterials show activity against Gram-positive and -negative pathogens

GlaxoSmithKline discloses new RIP-2 inhibitors

New agents for viral infections prepared by Vertex

Novel angiogenesis-promoting peptides patented in Korea

Dosing complete in phase II trial of oral PTH analogue in women with osteoporosis

Amicus closes recruitment in phase III Amigal study

Kinagen claims new protein kinase inhibitors

Promising 96-week data reported from phase II ocrelizumab trial in RRMS

FDA extends PDUFA date for Tysabri sBLA

Findings disclosed from ATON study evaluating atacicept in optic neuritis

Evotec and Apeiron Biologics collaborate on new target

Thrombogenics' ocriplasmin MAA accepted for review

Novel nitroxyl-releasing agents synthesized in U.S.

Isotechnika gives update on Luveniq strategy in Europe

Merck Serono to return full rights to Parkinson's disease candidate to Newron

OncoGenex Pharmaceuticals begins enrollment in OGX-427 study

Critical Outcome Technologies reports promising preclinical data on COTI-2

Protox Therapeutics' study of transrectal PRX-302 advances

EMA finds no link between cancer and use of angiotensin AT receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...